NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer

LESSONS LEARNED. NGR‐hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung cancer. Similar antitumor activity was observed in platinum‐sensitive and platinum‐resistant patient cohorts. BACKGROUND. Relapsed small cell lu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Gregorc, Vanesa, Cavina, Raffaele, Novello, Sivia, Grossi, Francesco, Lazzari, Chiara, Capelletto, Enrica, Genova, Carlo, Salini, Giulia, Lambiase, Antonio, Santoro, Armando
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2018
Gaiak:
Clinical Trial Results
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6263121/
https://ncbi.nlm.nih.gov/pubmed/30076277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0292
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak